General information
    ACovPid:ACoVP100418
    Trivial Name:N3G
    Amino Acids Sequence:(IEEIVKKIHHIERAIEAQQKLLQLTVWGIKQLQARIL)3
    Length:111
    C-Terminal Modification:None
    N-Terminal Modification:None
    Chemical Modification:None
    Peptide Source:

    Human immunodeficiency virus -1 gp41 : 33929200

    Source Description:We engineered the mimetic of the gp41 HR1 helical trimer, designated N3G, on the basis of the N37 sequence and the use of combined strategies, including isoleucine substitution at the a–d sites in the second heptad, intrahelical salt-bridge introduction i
    Against Virus:

    Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2) : 2697049

    Inhibition Value Type:IC50
    Inhibitory Effect:3.83 ± 0.5
    Inhibitory Unit:µM
    Target Domain Name:HR2 domain of SARS-CoV-2
    Assay:Cell–cell fusion assay
    Assay Description:According to the previous description, the SARS-CoV-2 S protein-mediated cell–cell fusion model was established. Briefly, the expression plasmid carrying SARS-CoV-2 S protein and EGFP (pAAV-SARS-CoV-2-S) was transfected into 293T to produce effector cells (293T/S/EGFP) for cell–cell fusion, and the empty expression plasmid (pAAV-IRES-EGFP) was used as a negative control (293T/EGFP). After transfection for 48 h, effector cells were collected in Dulbecco’s modified Eagle’s medium (DMEM) without FBS for cell–cell fusion. Six to eight hours before cell–cell fusion, the target cells (ACE2-293T) were plated at a density of 10^5 cells/well in a 96-well plate with complete medium. Then the supernatant was removed, and 10^4 effector cells were added to each well and incubated at 37 °C for 24 h. Finally, the cell–cell fusion was observed with a fluorescence microscope. To assess the inhibitory activity of peptides, gradient dilutions of peptides were added, and the cell–cell fusion was observed after co-incubation for 24 h. The percentage inhibition of cell–cell fusion was calculated according to the numbers of fused and unfused cells.
    Anti-CoV activity in vivo:
    Reference:33929200
    Comment:
    3D structure:

    Structure Experiment Verified:
    Similar Peptides:ACoVP100407   

    Target Domain information
    Target Domain Full Name:Heptad repeat 2 (HR2) domain of Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2) spike glycoprotein
    Target Type:glycoprotein
    UniprotID [Sequence]:

    P0DTC2 [1163-1202]

    Target Synonyms:Alternative name(s) for spike glycoprotein: E2 Peplomer protein S glycoprotein
    Target Source:

    Severe acute respiratory syndrome coronavirus 2 (2019-nCoV) (SARS-CoV-2) : 2697049

    Target Structure:6LVN, 6LXT, 6LZG, 6M0J, 6M17, 6M1V, 6VSB, 6VW1, 6VXX, 6VYB, 6W41, 6WPS, 6WPT, 6X29, 6X2A, 6X2B, 6X2C, 6X6P, 6X79, 6XC2, 6XC3, 6XC4, 6XC7, 6XCM, 6XCN, 6XDG, 6XE1, 6XEY, 6XF5, 6XF6, 6XKL, 6XKP, 6XKQ, 6XLU, 6XM0, 6XM3, 6XM4, 6XM5, 6XR8, 6XRA, 6XS6, 6YLA, 6YM0, 6YOR, 6YZ5, 6YZ7, 6Z2M, 6Z43, 6Z97, 6ZB4, 6ZB5, 6ZBP, 6ZCZ, 6ZDG, 6ZDH, 6ZER, 6ZFO, 6ZGE, 6ZGG, 6ZGI, 6ZH9, 6ZHD, 6ZLR, 6ZOW, 6ZOX, 6ZOY, 6ZOZ, 6ZP0, 6ZP1, 6ZP2, 6ZP5, 6ZP7, 6ZWV, 6ZXN, 7A25, 7A29, 7A4N, 7A5R, 7A5S, 7A91, 7A92, 7A93, 7A94, 7A95, 7A96, 7A97, 7A98, 7AD1, 7BWJ, 7BYR, 7BZ5, 7C01, 7C2L, 7C8D, 7C8V, 7C8W, 7CAB, 7CAH, 7CAI, 7CAK, 7CAN, 7CDI, 7CDJ, 7CH4, 7CH5, 7CHB, 7CHC, 7CHE, 7CHF, 7CHH, 7CJF, 7CN9, 7CT5, 7CWM, 7CWN, 7CWO, 7CWS, 7CWU, 7DCC, 7DCX, 7DD2, 7DD8, 7DDD, 7DDN, 7DF3, 7DF4, 7DK3, 7DK4, 7DK5, 7DK6, 7DK7, 7DMU, 7JJC, 7JJI, 7JJJ, 7JMO, 7JMP, 7JMW, 7JV2, 7JV4, 7JV6, 7JVA, 7JVB, 7JVC, 7JW0, 7JWB, 7JWY, 7JX3, 7JZL, 7JZM, 7JZN, 7JZU, 7K43, 7K45, 7K4N, 7K8M, 7K8S, 7K8T, 7K8U, 7K8V, 7K8W, 7K8X, 7K8Y, 7K8Z, 7K90, 7K9Z, 7KDG, 7KDH, 7KDI, 7KDJ, 7KDK, 7KDL, 7KE4, 7KE6, 7KE7, 7KE8, 7KE9, 7KEA, 7KEB, 7KEC, 7KJ2, 7KJ3, 7KJ4, 7KJ5, 7KKK, 7KKL, 7KL9, 7KMB, 7KMS, 7KMZ, 7KNB, 7KNE, 7KNH, 7KNI, 7L02, 7L06, 7L09